Not a good buy right now for an impatient entry: trend/positioning data still skew downside despite being near support.
Price is sitting near key support (~81.65); risk of a breakdown is meaningful given bearish moving-average stack.
Options positioning is bullish (low put/call), but high IV suggests the market is pricing elevated near-term moves—better for traders selling premium than chasing shares.
Fundamentals are improving sharply (strong Q3 2026 growth), but near-term technicals + hedge-fund selling keep the risk/reward unattractive for an immediate buy.
Wall Street “cons”: valuation/multiple risk, competitive/regulatory concerns, and expectation that the stock may need a new catalyst to re-rate.
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 117.09 USD with a low forecast of 89 USD and a high forecast of 129 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 117.09 USD with a low forecast of 89 USD and a high forecast of 129 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 79.220
Low
89
Averages
117.09
High
129
Current: 79.220
Low
89
Averages
117.09
High
129
Goldman Sachs
Neutral -> Sell
downgrade
$89
AI Analysis
2026-01-09
Reason
Goldman Sachs
Price Target
$89
AI Analysis
2026-01-09
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded HealthEquity to Sell from Neutral with an $89 price target. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. The firm thinks the stock's multiple will come under pressure until the next leg of growth opportunity emerges.
KeyBanc
Scott Schoenhaus
Overweight
maintain
$120 -> $125
2026-01-08
Reason
KeyBanc
Scott Schoenhaus
Price Target
$120 -> $125
2026-01-08
maintain
Overweight
Reason
KeyBanc analyst Scott Schoenhaus raised the firm's price target on HealthEquity to $125 from $120 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HQY
